Results 181 to 190 of about 13,918 (210)
Some of the next articles are maybe not open access.

Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).

International Journal of Radiation Oncology, Biology, Physics, 2023
PURPOSE/OBJECTIVE To determine the safety and tolerability of combining stereotactic ablative radiotherapy (SABR) and durvalumab with respect to rates of Grade ≥3 non-hematological toxicity in medically inoperable patients with early-stage non-small cell
Trudy C. Wu   +19 more
semanticscholar   +1 more source

NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).

Journal of Clinical Oncology, 2023
TPS4604 Background: The treatment for patients with metastatic RCC is evolving. The current standard of care for patients presenting with de novo metastatic disease is combination immunotherapy (IO)-based treatment.
W. Hall   +14 more
semanticscholar   +1 more source

Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the Kidney.

International Journal of Radiation Oncology, Biology, Physics
BACKGROUND While stereotactic ablative body radiotherapy (SABR) is associated with excellent local control for primary renal cell carcinoma (RCC), outcomes based on clear-cell (ccRCC) and non-clear cell (nccRCC) histologies are not well defined ...
Muhammad Ali   +25 more
semanticscholar   +1 more source

Stereotactic Ablative Body Radiotherapy (SABR) versus Radiofrequency Ablation and cryoablation for Primary Renal Cell Carcinoma: an economic evaluation of the FASTRACK II trial.

International Journal of Radiation Oncology, Biology, Physics
PURPOSE The Anonymized trial demonstrated the safety and efficacy of stereotactic ablative body radiotherapy (SABR) in patients with inoperable renal cell carcinoma (RCC).
Constanza Vargas   +16 more
semanticscholar   +1 more source

EVALUATION OF VOLUMETRIC RESPONSE ASSESSMENT FROM STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR RENAL CELL CARCINOMA (RCC).

International Journal of Radiation Oncology, Biology, Physics, 2023
PURPOSE Stereotactic ablative radiotherapy (SABR) is increasingly used to treat renal cell carcinoma (RCC). However, the optimal method to assess treatment response is unclear. We aimed to quantify changes in both volume and maximum linear size of tumors
D. Schep   +8 more
semanticscholar   +1 more source

Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase I study of Stereotactic Ablative Radiotherapy (SABR) for poly-metastatic disease.

International Journal of Radiation Oncology, Biology, Physics
PURPOSE This phase 1 study aimed to assess the safety and feasibility of SABR delivery to all sites of polymetastatic disease (>10 metastases). METHODS AND MATERIALS A 3+3 study design was used with five dose levels from 6 Gy (6 Gy x 1) to 30 Gy (6 Gy ...
Timothy K. Nguyen   +14 more
semanticscholar   +1 more source

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial

European Urology, 2018
BACKGROUND Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for oligometastatic prostate cancer. However, limited prospective evidence is available. OBJECTIVE To determine the safety and feasibility of single fraction SABR
Cristian Udovicich   +2 more
exaly   +2 more sources

Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial.

International Journal of Radiation Oncology, Biology, Physics, 2022
PURPOSE Despite increasing utilization of stereotactic ablative therapy (SABR) for oligometastatic cancer, prospective outcomes are lacking. The purpose of this study was to determine progression-free survival (PFS), local control (LC) and prognostic ...
S. Baker   +15 more
semanticscholar   +1 more source

Upfront versus Delayed Systemic Therapy in Patients with Oligometastatic Cancer Treated with Stereotactic Ablative Radiotherapy on the Phase II SABR-5 Trial.

International Journal of Radiation Oncology, Biology, Physics
PURPOSE The optimal sequencing of local and systemic therapy for oligometastatic cancer has not been established. This study retrospectively compared progression-free survival (PFS), overall survival (OS), and SABR-related toxicity between upfront versus
S. Baker   +32 more
semanticscholar   +1 more source

Systematic Review of Stereotactic Ablative Radiotherapy (SABR)/ Stereotactic Body Radiation Therapy (SBRT) for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.

Seminars in Thoracic and Cardiovascular Surgery
Stereotactic ablative radiotherapy (SABR) has emerged as an alternative, non-surgical treatment for high-risk patients with stage I non-small cell lung cancer (NSCLC) with increased use over time.
Andrea Wolf   +23 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy